Digoxin is the most commonly used digitalis glycoside for the treatment of congestive heart failure and atrial fibrillation. It is important to measure digoxin in serum from digitalized patients because the therapeutic range of serum digoxin concentration is narrow. Immunoassays are routinely used for therapeutic drug monitoring (TDM) of digoxin. The antibody with cross-reactivity to metabolites of digoxin (digoxigenin bis and monodigitoxosides, digoxigenin, and dihydrodigoxin) matching their relative cardio-activities should be used, and a good correlation must exist between the assay value and the pharmacological effect to avoid toxic dosage in the TDM of digoxin. [1] [2] [3] [4] [5] A receptor radioligand assay, using semi-purified Na ϩ /K ϩ -ATPase from a human heart, and a commercial immunoassay, the ACS TM Digoxin assay, using a monoclonal anti-digoxin antibody, satisfied almost all these conditions. 2, 4, 5) We recently reported the preparation of digoxin C-3Ј and C-3Љ hemisuccinate-bovine serum albumin (BSA) conjugates, the former of which was then used for generating a new anti-digoxin antiserum. Digoxin concentration in serum from digitalized patients was measured by the radioimmunoassay (RIA) using this antiserum. [6] [7] [8] In the present study, we prepared new anti-digoxin antisera against the BSA conjugates as well as new labeled antigens in which the C-3Ј or C-3Љ hemisuccinate derivative of digoxin was coupled with a [ 3 H]-leucine. RIA was carried out in homologous and site heterologous combinations between the antiserum and labeled antigen, and one of these systems was found to have a desirable recognition pattern for digoxin metabolites that matches the metabolite pharmacological activity. , and Dextran T-70 from Pharmacia Fine Chemicals (Uppsala, Sweden). Norit SX plus and other general reagents were supplied by Wako Pure Chemical Industries (Osaka, Japan). Digoxigenin, and its mono-and bis-digitoxosides were prepared by hydrolysis of digoxin according to the methods of Kaiser and his colleagues.
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MATERIALS AND METHODS

Materials
9)
A dextran-coated charcoal suspension was prepared by continuously stirring Norit SX plus (500 mg) and Dextran T-70 (50 mg) in cold phosphate saline buffer (40 ml) for 10 min prior to use.
The antisera (I-1), (I-2), and (I-3) were prepared by immunizing rabbits with digoxin 3Ј-hemisuccinate-BSA conjugate and the antisera (II-1), (II-2), and (II-3) by digoxin 3Љ-hemisuccinate-BSA conjugate.
7) The commercial antidigoxin BSA antiserum (III) was supplied by BioMakor Co. (Rehovot, Israel). Digoxin 3Ј-hemisuccinyl- [ 3 H]-leucine (5550 GBq/mmol) (7) was prepared by a previously reported method.
8)
Apparatus The melting point was determined with a Yanagimoto micro hot-stage apparatus and is uncorrected. Optical rotation was measured with a JASCO DIP-370 digital polarimeter. FAB-MS measurement was made on a JEOL HX-100 instrument equipped with a FAB ion source using glycerol and NaCl as the matrix agents. The UV spectrum was obtained with a Shimadzu UV-3000 recording spectrophotometer. 1 H-NMR spectra were recorded using tetra-methylsilane as an internal standard for a JEOL ECP-500 spectrometer at 500 MHz. Abbreviations used: sϭsinglet, dϭdoublet, and mϭmultiplet.
Digoxin 3Љ-Hemisuccinylleucine (6) Digoxin 3Љ-hemisuccinate p-nitrophenyl ester (4) was prepared from digoxin 3Љ-hemisuccinate (3). 7) A solution of L-leucine (87 mg, 0.66 mmol) in H 2 O (5 ml) was added to a solution of 4 (140 mg, 0.13 mmol) in pyridine (5 ml), and the mixture was stirred at room temperature for 18 h. The solution was extracted with AcOEt, and the aqueous layer was percolated through an Amberlite XAD-2 column (45ϫ1.5 cm i.d. . This clean-up procedure with a Sep-Pak silica cartridge was repeated 3 times and the resulting labeled compound was stored in MeOH at Ϫ18°C. RIA Procedure RIA was performed in phosphate saline buffer (pH 7.4) containing K 2 HPO 4 (0.696 g), NaH 2 PO 4 · H 2 O (0.138 g), NaCl (4.39 g), and BSA (1.0 g) in H 2 O (500 ml). For the digoxin free serum, a sample pool serum from healthy volunteers who had not taken any drugs was used. The digoxin free serum (0.2 ml), tracer (ca. 12000 dpm) in assay buffer (0.1 ml), and diluted antiserum (0.3 ml) were added to tubes containing from 0 to 10 ng of digoxin in assay buffer (0.1 ml). All tubes were shaken in a vortex mixer and incubated at 4°C for 3 h. A dextran-coated charcoal suspension (0.3 ml) was added to each tube, which was then vortexmixed, incubated for 10 min in an ice bath and centrifuged at 1700ϫg for 10 min at 4°C. The supernatant (0.7 ml) was transferred to a counting vial, a scintillation solution (6 ml) was added, and the radioactivity was counted in an Aloka LSC-6000 liquid scintillation counter. The radioactivity bound to the antibody was calculated after correction for the blank value measured using the assay buffer instead of the antiserum.
Cross-Reaction Study
The specificities of the antisera were tested by calculating the percentage of cross-reactivity with digoxigenin bisdigitoxoside, digoxigenin monodigitoxoside, digoxigenin, and dihydrodigoxin. 10, 11) Cross-reactivity was determined by the above-mentioned assay procedure, by comparing the concentrations of digoxin and test compounds necessary for a 50% displacement of the antibody-bound tracer.
RESULTS AND DISCUSSION
The sensitivity of RIA increases when a tracer with a higher specific radioactivity is used. Thus, a 125 I-labeled antigen is expected to provide a higher sensitivity than the corre- I-labeled tyrosine-digitoxigenin 3-hemisuccinate for measuring digitoxin in serum.
15) The design of this tracer was applied to 3 H-labeled antigen in the present study. The synthesis of digoxin 3Ј-and 3Љ-hemisuccinyl-[ H(N)]-leucine which has relatively high specific radioactivity. The radiochemical purity of the tracers was checked by TLC, using a previously reported method.
8) Digoxin 3Љ-hemisuccinylleucine (6) was prepared from digoxin 3Љ-hemisuccinate p-nitrophenyl ester (4), which was derived from 3 and used as a standard on TLC.
The properties of the antibodies are shown in Table 1 . The final dilutions were defined to bind approximately 50% of the tracer and the association constants were determined from a Scatchard plot. 16) When digoxin 3Ј-hemisuccinyl-[ 3 H]-leucine, which is the homologous antigen, was used, the sensitivities of the antisera (I) ((I-1), (I-2), (I-3)) elicited by digoxin 3Ј-hemisuccinate-BSA conjugate were higher than when digoxin 3Љ-hemisuccinyl- [ 3 H]-leucine, the site heterologous antigen was used. Also, these factors of the antisera (II) ((II-1), (II-2), (II-3)) elicited by digoxin 3Љ-hemisuccinate-BSA conjugate showed high potencies with use of the Chart 1 homologous antigen, except for the final dilution of antiserum (II-2). When the homologous antigen is used, low digoxin concentration levels can be measured.
The specificities of anti-digoxin antisera were assessed by cross-reaction tests with digoxin metabolites. Percentages indicating cross-reactivity at 50% displacement of the antibody-bound tracer compared to digoxin were calculated, and the results are listed in Table 2 . When the tracer with [ 3 H]-leucine at the C-3Ј position was used, antisera (I-1) had no significant cross-reaction with digoxigenin bisdigitoxoside, digoxigenin monodigitoxoside, or digoxigenin. In contrast, the antisera (II) showed high cross-reactivity with metabolites formed by the successive cleavage of the digitoxose residues. On the other hand, with digoxin 3Љ-hemisuccinyl-[ 3 H]-leucine, the antisera (II) were able to recognize the sugar moiety and the antisera (I) were inferior in terms of specificity. Antiserum (III) was a commercial antiserum produced by immunization with a hapten carrier protein conjugate, which was coupled to the terminal digitoxose of digoxin using periodate oxidation. 17, 18) When the tracer used digoxin 3Љ-hemisuccinyl- [ 3 H]-leucine, the specificities of antiserum (III) to the digitoxose chain were better than when digoxin 3Ј-hemisuccinyl-[ 7) The cross-reactivity pattern using [ 3 H]-digoxin was similar to the homologous RIA system in the present study. However, the RIA using [
3 H]-digoxin still lacks the sensitivity needed for measurement of digoxin concentration in serum, though it may be useful to investigate the specificity of anti-digoxin antiserum.
Immunoassays for cardiac glycosides are routinely used for TDM. It has been suggested that immunoassays for digoxin that cross-react to active metabolites are more comparable to the total biological activities of the drug, and a good correlation must exist between the assay value and the pharmacological effect. This RIA system using antiserum (I-3) with digoxin 3Ј-hemisuccinyl-[
3 H]-leucine meets this standard. Antiserum (I-3) showed digoxigenin bisdigitoxoside (76%), digoxigenin monodigitoxoside (65%), digoxigenin (26%), and dihydrodigoxin (1.2%). These cross-reactivity results agreed with the cardioactivity of digoxigenin bisdigitoxoside (77%), digoxigenin monodigitoxoside (66%), digoxigenin (4-21%), and dihydrodigoxin (2-6%). [19] [20] [21] The standard curve obtained with this RIA system is presented in Fig. 1 . The plot of logit percent bound radioactivity vs. logarithm of the amount of digoxin showed a linear relationship over the range of 0.03 to 3.0 ng. This study demonstrated that the RIA system using antiserum (I-3) with the homologous antigen would be useful in TDM of digoxin. The pharmacokinetics and TDM studies of digoxin may utilize novel anti-digoxin antisera. It was also shown that specificity of an antiserum can vary by combining a labeled-antigen having a different chemical structure. 
